Modality
Bispecific Ab
MOA
GLP-1/GIP
Target
AHR
Pathway
STING
FabryPSPPV
Development Pipeline
Preclinical
~Mar 2024
→ ~Jun 2025
Phase 1
Sep 2025
→ Dec 2026
Phase 1Current
NCT08326909
1,686 pts·PSP
2025-09→2026-12·Not yet recruiting
1,686 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-12-209mo awayPh2 Data· PSP
Trial Timeline
Q42026Q2Q3Q4
P1/2
Not yet…
Catalysts
Ph2 Data
2026-12-20 · 9mo away
PSP
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08326909 | Phase 1/2 | PSP | Not yet recr... | 1686 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| Doxalemzoparlimab | Nuvalent | Approved | AHR | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR |